The startup develops RNA-targeting technology to engage undruggable proteins and non-protein targets associated with cancer. This approach enables healthcare professionals to treat serious medical conditions that are currently unmanageable with traditional small molecule therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease-causing proteins and non-protein targets are considered "undruggable" by traditional small molecule therapies, leaving a significant gap in treatment options for various serious medical conditions. These limitations hinder the development of effective interventions for patients with inadequately served diseases.
Solution
Ranar Therapeutics is developing small molecule drugs that directly target RNA, enabling the modulation of previously inaccessible disease targets. Their approach utilizes a focused library of privileged chemical scaffolds to identify compounds that bind to RNA and disrupt its function. By leveraging a deep understanding of RNA structure and proprietary focused compounds, Ranar aims to expand the universe of druggable targets and address unmet medical needs. This technology opens avenues for novel patient treatments by targeting naked RNA with small molecule drugs.
Target Audience
The primary target audience includes healthcare professionals seeking new therapeutic options for serious medical conditions currently unmanageable with traditional small molecule therapies, as well as pharmaceutical companies looking to expand their drug discovery pipeline.
Features
- Focused library approach based on privileged chemical scaffolds for identifying RNA-binding compounds
- Proprietary compounds designed to alter RNA function
- Exclusive collaborations to enhance understanding of RNA structure
- Small molecule drugs designed to directly bind to RNA targets